COPD
Respiratory · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Progressive, largely irreversible airflow obstruction from noxious-particle exposure, chiefly smoking (and biomass in India). Management targets symptoms, exacerbations and smoking cessation.
Red flags
- Admit severe exacerbation, acidotic/worsening hypoxia, altered consciousness, poor social support or failure to respond
- Refer respiratory for diagnostic doubt, rapid decline, cor pulmonale, LTOT assessment, suspected alpha-1 deficiency, consideration of lung-volume reduction/transplant, or frequent exacerbations despite optimal therapy
Assessment
Investigations
- Post-bronchodilator spirometry (obstructive, limited reversibility; grade by FEV1% predicted)
- CXR (hyperinflation, bullae, exclude cancer/other), FBC (polycythaemia/anaemia/eosinophils), BMI, ECG/echo for cor pulmonale, ABG if SpO2 low, alpha-1 antitrypsin if indicated, sputum culture in exacerbations
Management
- Smoking cessation (biggest impact), vaccination (flu, pneumococcal, COVID), pulmonary rehab, treat comorbidities
- Inhaled: LABA+LAMA first-line; add ICS if eosinophilia or asthmatic features/exacerbations (triple therapy)
- Exacerbation: controlled oxygen 88-92%, nebulised bronchodilators, prednisolone 30 mg 5 days, antibiotics if purulent;
- NIV for persistent type II failure/acidosis
Disposition
Admit severe exacerbation, acidotic/worsening hypoxia, altered consciousness, poor social support or failure to respond.
Complications & pitfalls
- Recurrent exacerbations and hospitalisation; type II respiratory failure; cor pulmonale and right heart failure; pneumothorax from ruptured bullae; secondary polycythaemia; pneumonia; depression; cachexia; increased lung-cancer risk; death
Exam pearls
- In acute exacerbations give controlled oxygen targeting 88-92% via a 24-28% Venturi: uncontrolled high- flow oxygen can abolish hypoxic drive and precipitate CO2 narcosis. Repeat the ABG after 30-60 minutes.
- Monitoring & follow-up: Annual review (or 2x if severe): symptoms (mMRC/CAT), exacerbation frequency, FEV1 trend, inhaler technique, smoking status, SpO2, BMI, comorbidities. Assess for LTOT if PaO2 <=7.3 kPa stable (or <=8.0 with cor pulmonale/polycythaemia) when non-smoking; review need for rescue packs.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.